Significantly lower risk is seen for ICU admission, hospitalization, recovery, cases, and viral clearance. 11 studies from 9 independent teams in 7 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 46% [20‑64%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and after excluding studies using combined treatment and slightly worse for peer-reviewed studies.
Results are very robust — in exclusion sensitivity analysis 9 of 12 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.
Studies typically use advanced formulations for greatly improved bioavailability.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. The quality of non-prescription supplements varies widely1,2. All data and sources to reproduce this analysis are in the appendix.
Other meta analyses show significant improvements with quercetin for mortality3, ICU admission3,4, and hospitalization3,4.
2 meta analyses show significant improvements with quercetin for mortality
1,
ICU admission
1,2, and
hospitalization
1,2.
Covid Analysis et al., Dec 2024, preprint, 1 author.
